Key result
Transcatheter aortic valve replacement (TAVR) was successfully performed for severe critical aortic stenosis in a patient with active SLE, renal failure, and APS.
Why the study?
Can transcatheter aortic valve replacement (TAVR) be successfully performed in a patient with severe critical aortic stenosis, active SLE, renal failure, and APS?
Case Report (n=1)
Can transcatheter aortic valve replacement (TAVR) be successfully performed in a patient with severe critical aortic stenosis, active SLE, renal failure, and APS?
TAVR may represent a safer approach to cardiac valve replacement in high-surgical-risk patients with severe aortic stenosis and active systemic autoimmune disease.
Valvular heart disease is a relatively common finding in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), sometimes necessitating valve surgery. Valve replacement may result in significant early and late morbidity and mortality. Surgical risks are even greater when co-morbid conditions including active SLE and renal involvement are present. This is the first report of the successful use of transcatheter aortic valve replacement (TAVR) for severe critical aortic stenosis in a patient with active SLE, renal failure and APS. TAVR may represent an additional, safer, approach to cardiac valve replacement in appropriately selected patients particularly where surgical risk is high and active disease present.
No takes yet. Share an insight, caveat, or question.
Bert et al. (2013) conducted a case report in Severe critical aortic stenosis, active SLE, renal failure, and APS (n=1). Transcatheter aortic valve replacement (TAVR) was evaluated on Successful use of TAVR. Transcatheter aortic valve replacement (TAVR) was successfully performed for severe critical aortic stenosis in a patient with active SLE, renal failure, and APS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: